Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics - Top-Institutions - MDSpire

Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics

  • By

  • Zefeng Zhang

  • April 30, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hepatology
    • Immunology
    • Translational Medicine

  • #2

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hepatology
    • Immunology
    • Gastroenterology

  • #3

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Hepatology
    • Immunology
    • Precision Medicine

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Hepatology
    • Immunology
    • Clinical Research

  • #5

    King’s College London, King’s Liver Centre
    King’s College London, King’s Liver Centre

    London, N/A

    Key Differentiators

    • Hepatology
    • Immunology
    • Translational Research

Original Source(s)

Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics

  • by Zefeng Zhang

  • April 30, 2026

Related Content

Tzield Approval Expands to Younger Patients

First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes

VA DOD Updates Asthma Framework

The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.